Rx Product Updates (June 2016)

June 1st 2016

Read about the new Rx products featured in June 2016.

Tris Pharma

Indication:The FDA has approved Dyanavel XR, a central nervous system stimulant, for the treatment of attention-deficit/hyperactivity disorder in children 6 years or older. The recommended starting dose is 2.5 or 5 mg once daily in the morning. The dosage may be increased in increments of 2.5 to 10 mg/ day every 4 to 7 days until an optimal response is obtained.

Dosage Form:Extended-release oral suspension containing 2.5 mg of amphetamine base per mL

For More Information:trispharma.com

BASAGLARMarketed by:Eli Lilly and Company

Indication:The FDA has approved Basaglar (insulin glargine injection), a long-acting human insulin analog, for improving glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. The dosage should be individualized based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. Basaglar should be administered subcutaneously once daily at any time of day, but at the same time every day.

Dosage Form:Injection: 100 units/mL (U-100) in a 3-mL prefilled Basaglar Kwik- Pen delivery device

For More Information:basaglar.com

QUILLICHEW ERMarketed by:Pfizer

Indication:The FDA has approved Quilli- Chew ER (methylphenidate hydrochloride), a central nervous system stimulant, for the treatment of attention-deficit/hyperactivity disorder. For patients 6 years and older, the recommended starting dose is 20 mg orally, once daily in the morning. The dosage may be titrated weekly in increments of 10, 15, or 20 mg per day. A daily dosage above 60 mg is not recommended.

Dosage Form:Extended-release chewable tablets: 20 and 30 mg of methylphenidate hydrochloride (HCl), functionally scored. Extended-release chewable tablets: 40 mg of methylphenidate HCl, not scored

For More Information:pfizer.com/ products/product-detail/ quillichew_er

Related Content